Recent Finacing
Recent Raise
Callio Therapeutics, headquartered in Seattle and Singapore, develops multi-payload antibody-drug conjugates delivering combinations of payloads to tumor cells; its lead program is a HER2-targeted dual-payload ADC.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Callio Therapeutics.
